Vapotherm Inc (NYSE:VAPO) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 284,800 shares, a growth of 27.5% from the May 30th total of 223,300 shares. Based on an average daily volume of 43,500 shares, the days-to-cover ratio is currently 6.5 days. Approximately 3.4% of the company’s shares are sold short.
NYSE:VAPO opened at $20.36 on Friday. The company has a current ratio of 6.35, a quick ratio of 5.34 and a debt-to-equity ratio of 1.01. The company has a 50-day moving average price of $19.62. Vapotherm has a 1-year low of $14.70 and a 1-year high of $24.63.
Vapotherm (NYSE:VAPO) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.03. The company had revenue of $12.30 million during the quarter, compared to analyst estimates of $11.90 million. Equities analysts expect that Vapotherm will post -3.15 EPS for the current fiscal year.
Separately, Zacks Investment Research lowered shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Saturday, June 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.50.
Hedge funds have recently modified their holdings of the company. Pura Vida Investments LLC acquired a new position in shares of Vapotherm in the 4th quarter worth approximately $2,984,000. BlackRock Inc. acquired a new position in shares of Vapotherm in the 4th quarter worth approximately $6,248,000. Lord Abbett & CO. LLC acquired a new position in shares of Vapotherm in the 4th quarter worth approximately $7,573,000. Northern Trust Corp acquired a new position in shares of Vapotherm in the 4th quarter worth approximately $1,156,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Vapotherm in the 4th quarter worth approximately $118,000. Hedge funds and other institutional investors own 46.91% of the company’s stock.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Featured Article: Find a Trading Strategy That Works
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.